Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Basit Öğe Kaydı
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0001-7021-6139en_US
dc.authorid0000-0001-6543-5441en_US
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorCangır, Ayten Kayı
dc.contributor.authorFırat, Pınar
dc.contributor.authorErdem, Göker
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorOyan, Başak
dc.date.accessioned2024-01-25T06:51:14Z
dc.date.available2024-01-25T06:51:14Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractPleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic challenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncologists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.en_US
dc.identifier.citationKaplan, M. A., Şendur, M. A. H., Cangır, A. K., Fırat, P., Erdem, G., Kılıçkap, S. ve diğerleri. (2023). Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group. Current Problems in Cancer, 47(6), 101017.en_US
dc.identifier.doi10.1016/j.currproblcancer.2023.101017
dc.identifier.endpage15en_US
dc.identifier.issn0147-0272
dc.identifier.issue6
dc.identifier.pmid37845104
dc.identifier.scopus2-s2.0-85173875640
dc.identifier.scopusqualityQ2
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0147027223000703?via%3Dihub
dc.identifier.urihttps://hdl.handle.net/11468/13282
dc.identifier.volume47
dc.identifier.wosWOS:001125100500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaplan, Muhammet Ali
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofCurrent Problems in Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomarkeren_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectImmune checkpoint inhibitoren_US
dc.subjectImmunotherapyen_US
dc.subjectPleural mesotheliomaen_US
dc.titleEstablished and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Groupen_US
dc.titleEstablished and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Established and new treatment roadmaps for pleural mesothelioma.pdf
Boyut:
491.5 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu